ScholarIQanswers from OpenAlex

Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa

PaperCitations, authors & open-access status

Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa have?

ScholarIQcitation count

Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa has 30 citations in the OpenAlex counts ScholarIQ stores.

When was Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa published?

ScholarIQyear

Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa has 2023 year in the ScholarIQ index.

What is the open-access status of Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa?

ScholarIQoa status

Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa has gold oa status in the ScholarIQ index.

What is the DOI of Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa?

ScholarIQdoi

The DOI for Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa is on the source record.

What is the PMID of Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa?

ScholarIQpmid

The PMID for Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa is on the source record.

What is the OpenAlex record for Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa?

ScholarIQopenalex

The OpenAlex for Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial